Introduction
Wheezing illnesses associated with viral respiratory infections commonly herald the development of asthma in early childhood. Whether these infections are causal in asthma development is controversial. Through the years, the role of respiratory syncytial virus (RSV) bronchiolitis during early childhood in asthma development has been extensively scrutinized. There is evidence to show that children who wheeze with RSV infections during the first few years of life, particularly those who are hospitalized, are at increased risk of childhood asthma [1, 2] . With the development of molecular viral diagnostics, much has been learned over the past decade with respect to the role of previously undiscovered or underappreciated viruses as early childhood respiratory pathogens [3] . Perhaps most significantly, human rhinoviruses (HRVs) have been recognized as an extremely common cause of wheezing illnesses in early childhood and beyond [4] [5] [6] . In addition, wheezing during HRV infections has been strongly linked to subsequent asthma development [7 ] . The present review will focus on the mechanisms underlying host-susceptibility to HRV infections and the role HRVs play in early childhood wheezing and asthma development.
Epidemiology of wheezing in early childhood
The most common cause of wheezing during the first several years of life is infection with respiratory viruses, most commonly RSV, HRVs, and multiple virus infections. All children are infected with respiratory viruses during early childhood and nearly one-half wheeze during at least one of these infections [8] . A number of risk factors for wheezing with respiratory viruses during early childhood have been identified by birth-cohort studies. Maternal smoking, male sex, older siblings, and daycare attendance during infancy increase the risk for early childhood wheezing illnesses, whereas breastfeeding in the first months of life is likely protective against wheezing respiratory illnesses [8, 9] .
Although RSV is the predominant lower respiratory pathogen during the winter season in the Northern hemisphere, HRVs cause lower respiratory illnesses throughout the year and are the leading cause of wheezing
Purpose of review
To discuss the role of human rhinoviruses (HRVs) in early childhood wheezing illnesses and how HRVs contribute to the development of childhood asthma.
Recent findings
Advanced molecular diagnostics have identified HRVs as pathogens frequently causing wheezing illnesses in infants and young children. Wheezing during HRV infection in early life identifies children at particularly high-risk of asthma development. Plausible mechanisms by which HRV could cause airway damage, promote airway remodeling, and lead to asthma development have recently been identified. Summary HRV is a significant source of morbidity in infants and young children. The present review identifies mechanisms by which HRV lower respiratory tract infection, particularly in a susceptible host, could promote the development of childhood asthma. Further studies are needed to elucidate the mechanisms underlying the link between HRV wheezing in early childhood and subsequent asthma development, with the critical goal of identifying novel therapeutic and prevention strategies for both early childhood wheezing and asthma.
illnesses during spring and fall [4] . Recently, wheezing illnesses associated with HRV infection, both inpatient and outpatient, have been linked to more dramatic increases in persistent wheezing and asthma risk than wheezing illnesses associated with RSV [4,7 ,10] .
Human rhinovirus, an upper and lower respiratory pathogen
HRVs are the most frequent cause of the common cold and have traditionally been considered a pathogen isolated to the upper airway, in part because the ideal temperature for HRV replication is 33-358C. However, HRVs can and do invade and replicate in the lower airway following inoculation of the upper airway [11, 12] . Historically, HRVs have been divided into two groups (A and B) with 101 known serotypes. Tremendous efforts to better understand factors determining pathogenicity of HRVs are ongoing. Recently, full genome sequencing of the known HRV serotypes revealed a number of areas of the genome that could be important for virulence determination [13 ] . Another important observation from this sequencing effort was that HRVs can recombine to create new strains [13 ] . Many HRVs do not grow well in traditional cell culture, and this is particularly true for a novel group of HRVs, categorized as group C HRVs. Molecular diagnostics and characterization of HRVs have shown clearly that the number of HRV serotypes have previously been dramatically underestimated [14] . In the past several years, there has been an explosion of reports identifying novel group C HRVs and implicating them in both upper and lower respiratory tract illnesses [14,15 ,16 -18 ] . In fact, group C HRVs seem to be detected very frequently in children hospitalized for respiratory illnesses and asthma exacerbations [15 ,16 ,17 ] . Much remains to be learned about this newly discovered group of HRVs.
It is also important to note that HRVs (and other respiratory viruses) can lead to a broad spectrum of illness severity ( Fig. 1 ). Some infants and children infected with HRV may be asymptomatic, whereas others may have an illness severe enough to lead to hospitalization. This suggests that there may be host factors that play an important role in the severity of illnesses caused by HRVs. In addition, particular strains of HRV may be particularly pathogenic. A hybrid of these two concepts is that particular strains of HRV may cause more severe illnesses in susceptible hosts. Sorting out the relative 134 Paediatric asthma and development of atopy 
Virus detection
The present figure shows the rates of detection of respiratory viruses by illness severity during the first year of life in the Childhood Origins of Asthma (COAST) study and is updated from previously published data [4] to include virus identification by respiratory multicode assay [3] . HRV infections are associated with a broad range of symptom severity from asymptomatic to severe respiratory infection. HRV, human rhinovirus; NRVP, nonrhinovirus picornavirus; RSV, respiratory syncytial virus. , RSV; , HRV; , Parainfluenza; , Multiple virus; , NRVP; , Metapneumovirus; , Coronavirus; , Bocavirus; , Adenovirus.
contribution of host and virus-related factors toward asthma development are critical ongoing areas of investigation and could lead to new therapeutic and prevention strategies for wheezing illnesses and asthma.
The timing and cause of wheezing illnesses impact subsequent asthma risk RSV wheezing illnesses during the first few years of life, particularly those leading to hospitalization, have consistently been associated with an increased risk (two to three-fold) of subsequent asthma. With the increased ability to detect HRVs, data have emerged that indicate that wheezing with HRV is associated with a more pronounced risk of childhood asthma. Kotaniemi et al. [10] have shown that children who are hospitalized with HRV wheezing illnesses during the first 2 years of life are at increased risk (four-fold) of childhood asthma compared with children who were hospitalized with wheezing caused by other viruses.
Data from two birth cohorts have recently identified outpatient HRV-induced wheezing episodes during early childhood as an important risk factor for asthma as well. The Childhood Origins of Asthma (COAST) study is a high-risk birth cohort examining the role of respiratory viruses and immune dysregulation in the development of asthma and other allergic diseases [19] . COAST identified HRV wheezing illnesses during the first year of life as significant predictors of wheezing in the third year of life [4] and asthma at the age of 6 years [7 ] . In the COAST study, children with HRV wheezing illnesses and aeroallergen sensitization during infancy had the greatest risk of asthma at school age. In a very similar high-risk cohort in Australia, Kusel et al. [20] reported that HRV wheezing illnesses during the first year of life were associated with increased asthma risk at the age of 5 years, although this finding was restricted to children who developed aeroallergen sensitization by the age of 2 years. Thus, two birth cohorts, on separate continents, have identified HRV wheezing illnesses during infancy and aeroallergen sensitization as risk factors for childhood asthma development.
The COAST study has continued to evaluate the timing and specific viral cause of wheezing illnesses as the participants have progressed through early childhood. It appears that the age at which HRV wheezing illnesses occur has significant prognostic value with regard to subsequent risk of asthma. Children who wheezed with HRV during year 1 had an approximately three-fold risk of having asthma at the age of 6 years. HRV wheezing in year 2 was associated with a more pronounced increase in asthma risk [odds ratio (OR) 7], whereas wheezing with HRV infection during year 3 of life was associated with a dramatic (OR 32) increase in asthma at school age. Indeed, nearly 90% children who wheezed with HRV during the third year of life had asthma when they reached school age [7 ] .
Inflammation and airway changes in early childhood wheezing
Due to the limited ability to perform controlled invasive airway sampling for research purposes in infants and young children, there are limited data on the inflammatory and structural changes present in the airways of preschool wheezing children. Krawiec et al. [21] , utilizing bronchoscopy and bronchoalveolar lavage (BAL), demonstrated that children with persistent wheezing (median age 15 months) had increased cellularity and markers of inflammation compared with healthy controls, but did not have the characteristic eosinophil predominance seen in older children and adults with asthma. Similarly, Saglani et al. [22] using bronchoscopy and biopsy in children with persistent wheezing (median age 12 months) showed no eosinophilic inflammation or reticular basement membrane (RBM) thickening, another hallmark of asthma seen in older children and adults. In contrast, children with recurrent wheezing (median age 29 months) had both eosinophilic inflammation and RBM thickening when compared with controls, suggesting that changes typical of asthma in later childhood evolve in the airway between 1 and 3 years of age in recurrent wheezing children. Whether the viruses (frequently HRVs) causing recurrent wheezing illnesses in these children trigger or contribute to these inflammatory changes and RBM thickening in early childhood is currently unknown.
Natural history: intermittent virus-induced wheezing becomes persistent disease
For years clinicians have noted the progression from generally intermittent wheezing illnesses to persistent asthma during early childhood. Several attempts have been made to alter this 'natural history' of asthma development. The Preventing Early Asthma in Kids (PEAK) study [23] and the Prevention of Asthma in Childhood (PAC) study [24] utilized inhaled corticosteroids (ICS) in high-risk children to attempt to prevent asthma development. Both protocols were unsuccessful in altering the natural course of asthma, but PEAK clearly demonstrated symptomatic benefit for use of daily low-dose ICS in highrisk children with recurrent wheezing. In addition, PEAK clearly demonstrated the increased burden of symptoms (i.e. the development of persistent disease) that develops during early childhood [23] . Thus, during the same time frame (years 1-3) the children with recurrent wheezing evolve from having nonspecific airway inflammation [21, 22] to having airway changes typical of childhood asthma (eosinophilic predominance and RBM thickening) [25] , they begin to develop more persistent symptoms [23] , and the increased risk of having asthma at school age
The role of HRV infections in asthma development Jackson 135 associated with HRV wheezing illnesses climbs from OR of three to OR of 32 [7 ] . All of this clearly suggests that children who wheeze with HRV during the third year of life are not just at risk for asthma, but that they have asthma and any interventions directed at prevention need to be implemented before this point. Identifying novel therapeutic targets is critical and a better understanding of the host and virus-specific factors underlying the observed relationships between increased severity of HRV illnesses in early childhood and asthma development is required.
Host and environmental factors associated with wheezing illnesses and asthma
A number of host factors have been associated with increased risk of early childhood virus-induced wheezing illnesses. Some of these same factors have been associated with impaired responses to HRV infection in older individuals with asthma. Impaired peripheral blood interferon-g responses to both mitogens and viruses at birth have been associated with recurrent wheezing during infancy [26] . Similarly, reduced peripheral blood interferon-g response to mitogen at 9 months of age has been linked to an increased risk of wheezing in toddlers and school age children [27] . Interestingly, another important risk factor for asthma development, aeroallergen sensitization in early childhood [7 ,8,20,28] , is associated with reduced interferon-g responses as well.
A series of studies utilizing epithelial cells from patients with allergic asthma suggest that other types of interferon (b and l) responses are impaired in these individuals as well. In these studies, HRV infection of asthmatic airway epithelial cells led to decreased interferon production compared with controls, leading to increased viral replication and more severe asthma symptoms during infection [29, 30] . Thus, deficiencies in interferon responses in the peripheral blood as well as the airway have been associated with both recurrent wheezing and asthma, perhaps through a common mechanism of impaired innate immune response to virus infection.
Barrier function is also critical to the innate immune response, and impaired epithelial barrier function may also increase susceptibility to infection by respiratory viruses. Jakiela et al. [31 ] recently reported that HRV replication is enhanced in epithelial cell culture in an experimental model of airway damage. It is thus plausible to suggest that the variety of host factors (filaggrin mutation [32 ] ) and environmental factors (smoke exposure, pollution, virus infections, and allergens) that lead to disruption of barrier function could lead to enhanced viral replication and increase the severity of viral respiratory illnesses (including HRV) during early childhood, thus leading to airway damage, and asthma development. These same factors may also contribute to asthma exacerbation.
Human rhinoviruses promote inflammation and airway remodeling
HRV infections promote the expression of factors that have been associated with airway damage and remodeling. Recent studies have identified a number of potential pathways that could causally link recurrent HRV infection of the lower airway with airway remodeling and asthma development. Leigh et al. [33 ] reported that HRV infection of airway epithelial cells in vitro was associated with increased production of mediators involved in airway remodeling, including amphiregulin, activin A, and vascular endothelial growth factor (VEGF).
In this same study, the authors reported increased VEGF in nasal lavage fluid of volunteers with natural HRV infections as well. Recently, Zhu et al.
[34 ] demonstrated that HRV infection of epithelial cells also causes Tolllike receptor 3 (TLR-3)-dependent mucin production and upregulation of epidermal growth factor receptor, a prominent component of epithelial repair. Finally, microarray technology was utilized in an attempt to elucidate novel pathways important in response to HRV infection. Two separate studies to assess gene expression in epithelial cells during HRV infection identified upregulation of many genes in the interferon pathway as well as genes involved in airway remodeling [35 ,36 ] . In summary, these findings demonstrate that virus infections, and HRV in particular, can activate a number of proinflammatory and airway remodeling pathways that one could hypothesize may have deleterious effects on the rapidly growing airways of young children.
Human rhinoviruses and response to therapy
In general, preschool children with wheezing do not respond as well to typical therapies and utilize a disproportionate number of healthcare resources when compared with older children and adults with asthma [37] . Conventional therapies do not alter the natural history of the disease [23, 24] , although a recent post hoc analysis suggests that young children with wheezing illnesses associated with HRV may respond differently to prednisolone therapy than children with wheezing associated with other viruses [38] .
Recently, an uncontrolled trial [39] examining the effect of palivizumab (a monoclonal RSV antibody) on the development of recurrent wheezing in young children showed promising results, and a similar strategy aimed at HRV is desirable. To date, vaccines and other prevention strategies for HRV have proven elusive. However, new molecular technologies and the potential for identification of particularly virulent HRV strains could allow vaccine development in addition to new treatment strategies. Clinical studies attempting to identify particularly virulent groups or strains of HRV are ongoing and critical to the development of novel therapeutic and prevention strategies.
Conclusion
Advanced viral diagnostics have identified the importance of HRVs as both upper and lower respiratory pathogens. Wheezing illnesses caused by HRV in early childhood clearly identify children at increased risk of childhood asthma. Recent studies have identified plausible pathways by which HRV infection could be causal, particularly in a susceptible host, leading to airway damage, remodeling, and asthma (Fig. 2) . Whether particular strains of HRV are more pathogenic is an open and important question. Much has been learned in recent years regarding the role of HRVs in early childhood wheezing and asthma pathogenesis. However, novel therapeutic targets are needed to more effectively treat virus-induced wheezing, with the ultimate goal of interrupting the progression from intermittent virus-induced wheezing to childhood asthma. 
